Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : Incy save search
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.49 -1.21% -1.47% 1.2M
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.65%
H: 0.57%
C: -3.21%
first management drug application china
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
Published: 2023-12-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.36%
H: 0.03%
C: 0.03%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.2%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.18%
H: 0.56%
C: 0.38%
drug sirna treatment collaboration hypertension
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
Published: 2023-12-13 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.95%
H: 3.83%
C: 2.79%
tyvyt drug china
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published: 2023-11-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.69%
H: 1.66%
C: 1.66%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.34%
H: 0.37%
C: 0.3%
ibi351 drug granted review designation medical application china
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug application therapeutics
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 13:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug medical application therapeutics china
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.5%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.4%
H: 0.75%
C: -1.21%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.21%
H: 1.66%
C: 1.46%
drug tyvyt china
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation drug medical application granted review china
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 01:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-20 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.27%
H: 0.22%
C: -1.55%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 2.32%
H: 1.21%
C: 0.99%
treatment designation pharma drug application granted review china
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 17:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
drug application injection
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
bevagen approval food drug
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
SANA | $7.73 -6.42% -6.72% 1.9M
|
|
| O: 5.56%
H: 2.46%
C: -13.16%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
treatment drug application
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
SANA | $7.73 -6.42% -6.72% 1.9M
|
|
| O: -6.1%
H: 9.2%
C: 8.6%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.4%
H: 0.25%
C: -0.07%
treatment drug application
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.3%
H: 0.85%
C: -2.08%
new drug treatment fda application ces drug
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
Incyte Withdraws Lymphoma Drug in "Business Decision"
Published: 2022-01-26 (Crawled : 16:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -1.27%
H: 2.58%
C: 0.42%
drug
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.